Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial.

ABSTRACT:

Background

Despite evidence associating inflammatory biomarkers with worse outcomes in hospitalized adults with COVID-19, trials of immunomodulatory therapies have met with mixed results, likely due in part to biological heterogeneity of participants. Latent class analysis (LCA) of clinical and protein biomarker data has identified two subtypes of non-COVID acute respiratory distress syndrome (ARDS) with different clinical outcomes and treatment responses. We studied biological heterogeneity and clinical outcomes in a multi-institutional platform randomized controlled trial of adults with severe COVID-19 hypoxemic respiratory failure (I-SPY COVID).

Methods

Clinical and plasma protein biomarker data were analyzed from 400 trial participants enrolled from September 2020 until

SUBMITTER: Alipanah-Lechner N 

PROVIDER: S-EPMC10882728 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature